Proteomics-based target identification: bengamides as a new class of methionine aminopeptidase inhibitors |
| |
Authors: | Towbin Harry Bair Kenneth W DeCaprio James A Eck Michael J Kim Sunkyu Kinder Frederick R Morollo Anthony Mueller Dieter R Schindler Patrick Song Hyun Kyu van Oostrum Jan Versace Richard W Voshol Hans Wood Jeanette Zabludoff Sonya Phillips Penny E |
| |
Affiliation: | Novartis Pharma AG, CH-4036 Basle, Switzerland. |
| |
Abstract: | LAF389 is a synthetic analogue of bengamides, a class of marine natural products that produce inhibitory effects on tumor growth in vitro and in vivo. A proteomics-based approach has been used to identify signaling pathways affected by bengamides. LAF389 treatment of cells resulted in altered mobility of a subset of proteins on two-dimensional gel electrophoresis. Detailed analysis of one of the proteins, 14-3-3gamma, showed that bengamide treatment resulted in retention of the amino-terminal methionine, suggesting that bengamides directly or indirectly inhibited methionine aminopeptidases (MetAps). Both known MetAps are inhibited by LAF389. Short interfering RNA suppression of MetAp2 also altered amino-terminal processing of 14-3-3gamma. A high resolution structure of human MetAp2 co-crystallized with a bengamide shows that the compound binds in a manner that mimics peptide substrates. Additionally, the structure reveals that three key hydroxyl groups on the inhibitor coordinate the di-cobalt center in the enzyme active site. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|